This trial tests the safety, effectiveness and tolerance of a new HIV-1 treatment for people who haven't had any treatment before.
4 Primary · 10 Secondary · Reporting Duration: Baseline (Day 1) and Week 96
2 Treatment Groups
1 of 2
1 of 2
500 Total Participants · 2 Treatment Groups
Primary Treatment: DOR/ISL · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are participants still being accepted for this research?
"As indicated on clinicaltrials.gov, new participants are being welcomed into this medical trial that was first announced on March 8th 2023 and further revised 14 days later." - Anonymous Online Contributor
What potential risks might patients encounter with DOR/ISL treatments?
"Our evaluation by Power granted DOR/ISL a score of 3 due to the prior clinical data validating its safety, as this is an advanced Phase 3 trial." - Anonymous Online Contributor
What are the major goals of this clinical experiment?
"Per Merck Sharp & Dohme LLC, the primary outcome which will be tracked over 48 weeks is the Percentage of participants with human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL at Week 48. Secondary outcomes being evaluated include Percentage of participants experiencing any Adverse Events in a 96 week timeframe, Percentage of those discontinuing from study treatment due to an AE through Week 96 and finally the Percentage of individuals with HIV-1 RNA <50 copies/mL at Week 96 using PCR assays that detect lower than 50 copies/ml." - Anonymous Online Contributor
What is the current participant pool for this research endeavor?
"Indeed, data hosted on clinicaltrials.gov affirms that this medical study is presently recruiting patients. First posted on March 8th 2023, the trial requires 500 participants from a single site for completion." - Anonymous Online Contributor